Respiratory Market Insight 2008 : Market Research Report

Respiratory Market Insight 2008

Published by: Visiongain

Published: Feb. 11, 2008 - 135 Pages

Chapter 1 Executive Summary: 1.1 The Respiratory Treatment Market Has High Potential; 1.2 Combination Class Leads the Market; 1.3 GSK Dominates the Market; 1.4 Aims, Scope and Format of the Report
Chapter 2 Introduction: 2.1 Respiratory Diseases Overview; 2.2 What is Asthma?; 2.3 Chronic Obstructive Pulmonary Disease (COPD); 2.4 Upper Respiratory Infections (URI); 2.5 Major Drug Classes in Treating Respiratory Diseases
Chapter 3 The Global Respiratory Disease Drug Market: 3.1 The Global Respiratory Disease Drug Market Will Grow During 2008-2013; 3.2 GSK Currently Leads the Respiratory Market; 3.3 Combination Drugs to Continue Their Domination of the Respiratory Disease Market, 2006 Onwards; 3.4 Other Classes of Respiratory Drugs Will Display High Revenues during 2006-2013; 3.5 Antihistamines - Declining Revenues due to Heightened Competition; 3.6 B2-Stimulants - Will This Class Be Superseded by the Combination Drugs?; 3.7 Corticosteroids - Carving a Secure Niche in a Highly Competitive Market; 3.8 Leukotriene Inhibitors Will Maintain a Respected Position in the Respiratory Market; 3.9 Competition in the Respiratory Disease Drug Market to Become Increasingly Intense
Chapter 4 The World Market for Combination Drugs, 2008-2013: 4.1 Combination Drugs - Strong Growth Leads to Continuing Predominance in the Market; 4.2 GSK’s Advair/Seretide Currently Leads the Respiratory Market; 4.3 Symbicort - High Revenues Followed by Decline; 4.4 Combivent Will Reach Blockbuster Status
Chapter 5 The World Market for Antihistamines, 2008-2013: 5.1 Increased Competition Will Lower Revenues Among the Antihistamines; 5.2 Will Pfizer’s Zyrtec Still Dominate the Antihistamine Market After Patent Expiration?; 5.3 Allegra/Telfast Will Decline in Revenue; 5.4 Clarinex/Aerius Will Show Some Positive Growth but then Gradually Decline
Chapter 6 The World Market for Corticosteroids, 2008-2013: 6.1 Corticosteroids Will Retain Their Niche Despite a Marked Decline in Sales; 6.2 Pulmicort from AstraZeneca is the Market Leader - But will it Last?; 6.3 Flovent/Flixotide Will Gradually Decline in Sales; 6.4 Nasonex Will Become the Leading Product in this Market; 6.5 Summary - Corticosteroids
Chapter 7 The World Market for Leukotriene Inhibitors, 2008-2013: 7.1 Singulair Dominates the Leukotriene Inhibitor Class; 7.2 Summary - Leukotriene Inhibitors
Chapter 8 The World Market for Monoclonal Antibodies, 2008-2013: 8.1 The Monoclonal Antibodies Will Face Decreased Growth; 8.2 MedImmune’s Synagis Leads This Market; 8.3 Xolair Shows Steady Growth - Will it Become the New Market Leader?
Chapter 9 The World Market for B2-Stimulants, 2008-2013: 9.1 B2-Stimulants Will Lose Prominence in the Respiratory Market; 9.2 Xopenex Will Dominate the B2-Stimulants Class Despite Mixed Growth; 9.3 Serevent Loses Revenue Despite Patent Protection; 9.4 Recent Study Confirms Increased Risk With Beta-2 Agonist Usage; 9.5 Summary - Beta-2 Agonists
Chapter 10 Analysis of Factors That Influence the Respiratory Market: 10.1 SWOT Analysis of the Respiratory Market; 10.2 An Expanding Patient Population Constitutes the Principal Driver in the Respiratory Market; 10.3 The Principal Restraints in the Respiratory Market; 10.4 What has Caused a Broadening of the Focus in Respiratory Drug Development?; 10.5 Respiratory Disease - A Unique Market Based on Management Rather than Cure; 10.6 Increasing Investment in the ‘Cinderella Sector’; 10.7 The Future for Respiratory Disease Research and Development and the Increasing Focus on; COPD; 10.8 The Importance of Education in the Future of the Respiratory Disease Market; 10.9 Is the Early Treatment of Asthma the Way Ahead?
Chapter 11 Respiratory Pipeline Products: 11.1 Summary of All Respiratory Pipeline Products; 11.2 The Respiratory Pipeline is Large; 11.3 NVA237 and QVA149 for COPD; 11.4 New Companies Seek Entrance Into a Potentially Lucrative Market; 11.5 The Potential of the Respiratory Market Has Encouraged R&D; 11.6 Innovation Rules For Early Stage Pipeline Drugs; 11.7 Respiratory Pipeline Shows Short- and Long-Term Potential
Chapter 12 Conclusion: 12.1 The Respiratory Market Constitutes a High Revenue Market with Continuing Growth Potential; 12.2 Combination Class Will Dominate During the Forecast Period; 12.3 Unmet Needs in the Market; 12.4 Future Opportunities in the Respiratory Market
List of Tables: Table 1.1 Blockbuster Drugs in the World Respiratory Market; Table 2.1 Summary of the Major Products in the Respiratory Market and Revenues ($m), 2006; Table 3.1 Blockbuster Drugs in the World Respiratory Disease Market, 2006; Table 3.2 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013; Table 3.3 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Respiratory Drugs by Class, 2006 & 2013; Table 4.1 World Revenues ($m) for Combination Drugs, 2008-2013; Table 4.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Combination Drugs, 2006 & 2013; Table 5.1 World Revenues ($m) for Antihistamines, 2008-2013; Table 5.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Antihistamines, 2006 & 2013; Table 6.1, World Revenues ($m) for Corticosteroids, 2008-2013; Table 6.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Corticosteroids, 2006 & 2013; Table 7.1 World Revenues ($m) and Growth Rate (%) for Singulair, 2008-2013; Table 8.1 World Revenues ($m) for Monoclonal Antibodies, 2008-2013; Table 8.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Monoclonal Antibodies, 2006 & 2013; Table 9.1 World Revenues ($m) for B2-Stimulants, 2008-2013; Table 9.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for B2-Stimulants, 2006 & 2013; Table 10.1 A SWOT Chart for the Respiratory Market, 2008-2013; Table 11.1 Pipeline Drugs for Respiratory Diseases, 2008
List of Figures: Figure 1.1 Market Share (%) for the Respiratory Market by Company, 2006; Figure 3.1 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013; Figure 3.2 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013; Figure 3.3 World Market Share (%) for Respiratory Drugs by Class, 2006; Figure 3.4 World Market Share (%) for Respiratory Drugs by Class, 2013; Figure 4.1 Total World Revenues ($m) for Combination Drugs, 2008-2013; Figure 4.2 World Revenues ($m) for the Combination Drugs by Leading Product, 2008-2013; Figure 4.3 World Market Share (%) for Combination Drugs by Leading Product, 2006; Figure 4.4 World Market Share (%) for Combination Drugs by Leading Product, 2013; Figure 4.5 World Advair/Seretide Revenues ($m), 2008-2013; Figure 4.6 World Symbicort Revenues ($m), 2008-2013; Figure 4.7 World Combivent Revenues ($m), 2008-2013; Figure 5.1 Total World Revenues ($m) for Antihistamines, 2008-2013; Figure 5.2 World Revenues ($m) for the Antihistamines by Leading Product, 2008-2013; Figure 5.3 World Market Share (%) for Antihistamines by Product, 2006; Figure 5.4 World Market Share (%) for Antihistamines by Product, 2013; Figure 5.5 World Zyrtec Revenues ($m), 2008-2013; Figure 5.6 World Allegra/Telfast Revenues ($m), 2008-2013; Figure 5.7 World Clarinex/Aerius Revenues ($m), 2008-2013; Figure 6.1 Total World Revenues ($m) for Corticosteroids, 2008-2013; Figure 6.2 World Revenues ($m) for the Corticosteroids by Leading Product, 2008-2013; Figure 6.3 World Market Share (%) for Corticosteroids, 2006; Figure 6.4 World Market Share (%) for Corticosteroids, 2013; Figure 6.5 World Pulmicort Revenues ($m), 2008-2013; Figure 6.6 Flovent/Flixotide Revenues ($m), 2008-2013; Figure 6.7 World Nasonex Revenues ($m), 2008-2013; Figure 7.1 World Revenues ($m) for Singulair, 2008-2013; Figure 8.1 Total World Revenues ($m) for Monoclonal Antibodies, 2008-2013; Figure 8.2 World Revenues ($m) for the Monoclonal Antibodies by Leading Product, 2008-2013; Figure 8.3 World Market Share (%) for Monoclonal Antibodies, 2006; Figure 8.4 World Market Share (%) for Monoclonal Antibodies, 2013; Figure 8.5 World Synagis Revenues ($m), 2008-2013; Figure 8.6 World Xolair Revenues ($m), 2008-2013; Figure 9.1 Total World Revenues ($m) for B2-Stimulants, 2008-2013; Figure 9.2 World Revenues ($m) for the B2-Stimulants by Leading Product, 2008-2013; Figure 9.3 World Market Share (%) for B2-Stimulants, 2006; Figure 9.4 World Market Share (%) for B2-Stimulants, 2013; Figure 9.5 World Xopenex Revenues ($m), 2008-2013; Figure 9.6 World Serevent Revenues ($m), 2008-2013

Abstract

This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies. The respiratory market generated revenues of $30503m in 2006, but what will it be in 2013,? Which year will see it reach its peak? This report tells you.

The respiratory market contained ten blockbuster drugs in 2006, with the top three being; Advair/Seretide, Singulair and Zyrtec. Visiongain predicts that there will be room for more blockbusters as the current products lose patent protection. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.

The prevalence of respiratory diseases such as asthma, in the leading pharmaceutical markets, has increased significantly over the past few decades. Although there is some evidence to suggest that the rate of increase is slowing, we believe that the prevalence will continue to increase and be a key driver of this market throughout the forecast period of the report.

Sources include primary interviews and analysis unavailable elsewhere, in-house industry databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Respiratory Market concentrates on the following essential aspects of the market:

Discussion of the current pharmaceutical market
Forecast of the worldwide pharmaceutical market from 2008-2013
Drivers and restraints facing the respiratory market
Opportunities and threats facing the respiratory market
Growth of the respiratory drugs market between 2008-2013
Commercial prospects for the market-leading drugs, with sales forecasts from 2008-2013
Individual forecasts of the leading drug classes from 2008-2013
The potential of generics manufacturers to penetrate this market
Pipeline developments with blockbuster potential
Currently marketed drugs with blockbuster potential
Discussion of unmet therapeutic needs and relative advantages of products

Why you should buy this report:

To receive a comprehensive analysis of the prospects for respiratory drugs from 2008-2013
To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2008-2013
To determine key activities of leading companies
To discover “hot” pipeline developments and up-and-coming products

To determine the forces that influence the market for respiratory products:

Competitive characteristics of the market
Drivers
Restraints
Strengths, weaknesses, opportunities and threats (SWOT analysis)
To find out where the market is heading - both technologically and commercially

Do you know what the market values of these major therapeutic areas of the respiratory market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC respiratory drugs by product type. The study also assess' the challenges faced by respiratory companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?

This report features over 40 figures & graphs, 15 tables and charts, news, insights, the latest developments and an in depth survey of the respiratory market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Respiratory Market Insight 2008

Table of Contents

Abstract